EGFR and non-small cell lung carcinoma: Specifically, their interaction with the E3 ubiquitin ligase CBL is impaired, leading to defective ubiquitination and degradation.[10] The aberrant endocytic trafficking of EGFR is known to drive sustained and pathogenic signaling,[4c] yet multiple questions regarding the pathway and regulation of the trafficking and endosomal signaling of EGFR in TKI‐resistant NSCLC remain unanswered.[11]